Our main hypotheses were as follows: (a) that plasma TG/HDL-C ratio is a clinical biomarker that associates with measures of longitudinal cognitive decline in MCI and dementia and (b) both plasma and CSF levels of ApoA1 equally associate with measures of longitudinal cognitive decline in MCI and dementia. This evidence concerns the gene APOA1 and dementia.